1. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: A randomised clinical trial on overall survival
- Author
-
Wilfried Tröger, Agnes Schumann, Nikola Stankovic, Marcus Reif, Danijel Galun, and Miroslav Milicevic
- Subjects
Male ,Oncology ,Cancer Research ,Kaplan-Meier Estimate ,law.invention ,0302 clinical medicine ,Randomized controlled trial ,law ,Prospective Studies ,Neoplasm Metastasis ,Pancreatic neoplasm ,Prospective cohort study ,Randomised controlled trial ,Aged, 80 and over ,0303 health sciences ,biology ,Headache ,Middle Aged ,Mistletoe ,3. Good health ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Adult ,medicine.medical_specialty ,Viscum album ,Disease-Free Survival ,Drug Administration Schedule ,03 medical and health sciences ,Internal medicine ,Pancreatic cancer ,medicine ,Humans ,Survival analysis ,Aged ,030304 developmental biology ,Dose-Response Relationship, Drug ,Plant Extracts ,business.industry ,Cancer ,Interim analysis ,medicine.disease ,biology.organism_classification ,Surgery ,Pancreatic Neoplasms ,Clinical trial ,Back Pain ,business - Abstract
BackgroundThe unfavourable side-effects of late-stage pancreatic cancer treatments call for non-toxic and effective therapeutic approaches. We compared the overall survival (OS) of patients receiving an extract of Viscum album [L.] (VaL) or no antineoplastic therapy.MethodsThis is a prospective, parallel, open label, monocentre, group-sequential, randomised phase III study. Patients with locally advanced or metastatic cancer of the pancreas were stratified according to a binary prognosis index, composed of tumour stage, age and performance status; and were evenly randomised to subcutaneous injections of VaL extracts or no antineoplastic therapy (control). VaL was applied in a dose-escalating manner from 0.01mg up to 10mg three times per week. Patients in both groups received best supportive care. The primary end-point was 12-month OS, assessed in a group-sequential analysis.FindingsWe present the first interim analysis, including data from 220 patients. Baseline characteristics were well balanced between the study arms. Median OS was 4.8 for VaL and 2.7months for control patients (prognosis-adjusted hazard ratio, HR=0.49; p
- Published
- 2013
- Full Text
- View/download PDF